アジソン病診断・治療の世界市場：2022-2028年

世界のアジソン病の市場規模は予測期間中に高いCAGRを示すと予測されています。

アジソン病の有病率の上昇、新薬開発のための製薬会社によるR&D活動の増加、これらの疾患や治療に対する意識の高まりなどの要因が同市場の成長を促進する主な要因の一部となっています。また、医療制度の発展、治療費削減のための技術革新、これらの疾患の治療のための新薬のFDA承認なども予測期間中の市場に有利な機会を示す見通しです。

当レポートでは、世界のアジソン病診断・治療の市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 市場概要・洞察

第3章 競合情勢

• 主要企業分析
• 主要戦略分析
• COVID-19の主要企業への影響

第4章 市場決定要因

• 推進要因
• 抑制要因
• 機会

第5章 市場分析：区分別

• 世界のアジソン病市場：診断別
  • ラボ試験
  • 画像テスト
• 世界のアジソン病市場：治療別
  • 経口コルチコステロイド
  • コルチコステロイド注射
• 世界のアジソン病市場：エンドユーザー別
  • 病院・診療所
  • 診断ラボ

第6章 地域分析

• 北米
• 欧州
• アジア太平洋
• その他の地域

第7章 企業プロファイル

• Boehringer Ingelheim International GmbH.
• Diurnal Group plc
• GlaxoSmithKline plc
• Laboratory Corporation of America
• Lupin Pharmaceuticals, Inc.,
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Tocris Bioscience
• Trinity Biotech PLC
• ViroPharma

LIST OF TABLES

• 1. GLOBAL ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 2. GLOBAL LABORATORY TESTING IN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 3. GLOBAL IMAGING TESTE IN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 4. GLOBAL ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT 2020-2027($ MILLION)
• 5. GLOBAL ORAL CORTICOSTEROIDS FOR ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 6. GLOBAL CORTICOSTEROIDS INJECTIONS FOR ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 7. GLOBAL ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
• 8. GLOBAL HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 9. GLOBAL DIAGNOSTIC LABORATORIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 10. NORTH AMERICAN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 11. NORTH AMERICAN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 12. NORTH AMERICAN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
• 13. NORTH AMERICAN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
• 14. EUROPEAN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 15. EUROPEAN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 16. EUROPEAN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
• 17. EUROPEAN ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
• 18. ASIA-PACIFIC ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 19. ASIA-PACIFIC ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 20. ASIA-PACIFIC ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT 2020-2027($ MILLION)
• 21. ASIA-PACIFIC ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
• 22. REST OF THE WORLD ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 23. REST OF THE WORLD ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 24. REST OF THE WORLD ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT 2020-2027($ MILLION)
• 25. REST OF THE WORLD ADDISON'S DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)

LIST OF FIGURES

• 1. GLOBAL ADDISON'S DISEASE MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
• 2. GLOBAL ADDISON'S DISEASE MARKET SHARE BY TREATMENT 2020 VS 2027 (%)
• 3. GLOBAL ADDISON'S DISEASE MARKET SHARE BY END-USER, 2020 VS 2027 (%)
• 4. GLOBAL ADDISON'S DISEASE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
• 5. GLOBAL LABORATORY TESTING IN ADDISON'S DISEASE MARKET SHARE BY REGION, 2020-2027 ($ MILLION)
• 6. GLOBAL IMAGING TESTE IN ADDISON'S DISEASE MARKET SHARE BY REGION, 2020-2027 (%)
• 7. GLOBAL ORACORTICOSTEROIDS FOR ADDISON'S DISEASE MARKET SHARE BY REGION, 2020-2027 (%)
• 8. GLOBAL CORTICOSTEROIDS INJECTIONS ADDISON'S DISEASE MARKET SHARE BY REGION, 2020-2027 (%)
• 9. GLOBAL HOSPITALS AND CLINICS MARKET SHARE BY REGION, 2020-2027 (%)
• 10. GLOBAL DIAGNOSTIC LABORATORIES MARKET SHARE BY REGION, 2020-2027 (%)
• 11. US ADDISON'S DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
• 12. CANADA ADDISON'S DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
• 13. UK ADDISON'S DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
• 14. FRANCE ADDISON'S DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
• 15. GERMANY ADDISON'S DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
• 16. ITALY ADDISON'S DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
• 17. SPAIN ADDISON'S DISEASE MARKET SIZE, 2020-2027 ($ MILLION)
• 18. REST OF EUROPE ADDISON'S DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 19. INDIA ADDISON'S DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 20. CHINA ADDISON'S DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 21. JAPAN ADDISON'S DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 22. SOUTH KOREA ADDISON'S DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 23. REST OF ASIA-PACIFIC ADDISON'S DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 24. REST OF THE WORLD ADDISON'S DISEASE MARKET SIZE, 2020-2027($ MILLION)

Global Addison's Disease Market Size, Share & Trends Analysis Report by Diagnosis (Laboratory Testing and Imaging Tests), By Treatment (Oral Corticosteroid and Corticosteroid Injections), By End User (Hospitals and Clinics, and Diagnostic Laboratories) Forecast 2021-2027

The global market for Addison's disease is projected to have a considerable CAGR during the forecast period. Addison's disease, which is also known as adrenal insufficiency, is a disorder that occurs due to a lack of enough production of certain hormones (chemicals that control the function of tissues or organs.). In Addison's disease, the adrenal glands, located just above the kidneys, produce too little cortisol and, often, too little aldosterone. The disease affects all age groups and both male and female however is most common in the 30-50-year-old age range. The cause of the occurrence of Addison's disease includes Injury to the adrenal glands, Bleeding into the adrenal glands, infection such as tuberculosis and HIV/AIDS, and other Genetic defects. Apart from this, extreme fatigue, weight loss and decreased appetite, darkening of your skin (hyperpigmentation), nausea, diarrhea or vomiting (gastrointestinal symptoms), irritability, and depression or other behavioral symptoms are some of the major problems associated with Addison's disease.

The rising prevalence of Addison's diseases, increasing R&D activities by pharmaceutical companies in order to develop new drugs, and growing awareness regarding these diseases and treatment associated with them, are some of the major factors that drive the growth of Addison's disease market. According to the American Academy of Family Physicians Foundation, in the US, and Western Europe, the estimated prevalence of Addison disease is one in 20,000 persons. Thus, the rising prevalence of these diseases demands effective treatments and drugs to cure them, which leads to the growth of the market. However, the lack of awareness and lack of proper diagnosis acts in the early stage of the disease can become the restraining factor to the market. The development in healthcare systems, and technological innovation to decline the cost of the treatments, and FDA approvals for the novel drugs for the treatment for these diseases offer lucrative opportunities to the market during the forecast period.

Segmental Outlook

The global Addison's disease market is segmented based on diagnosis, treatment, and end-user. On the basis of diagnosis, the market is segmented into laboratory testing and imaging tests. The laboratory testing by treatment segment is anticipated to grow significantly during the forecast period. Laboratory testing comprises many tests including blood test, ACTH stimulation test, insulin-induced hypoglycemia test, and other tests which are important for the treatment of these diseases. Among these tests, the ACTH stimulation test is expected to be the fastest-growing market due to the low cost of the diagnosis method. The test measures how well the adrenal glands respond to adrenocorticotropic hormone (ACTH). Thus, the rising prevalence of Addison's diseases will demand these laboratory test which in turn, further drive the market growth. By application, the global Addison's disease market is categorized into oral corticosteroid and corticosteroid injections. Similarly, based on end-user, it is divided into hospitals & clinics, and diagnostic laboratories.

Global Addison's Disease Market Share by Treatment, 2020 (%)

Global Addison's Disease Market Share By Treatment

Oral Corticosteroids holds the Major Market Share in Addison's Disease Market

Among treatment, the oral corticosteroids held the major share in 2020, and it is projected to grow at a considerable CAGR during the forecast period. Oral corticosteroids are taken in pill or liquid form. Oral drugs are considered as the first-line treatment due to easy availability and ease of drugs administration. These medicines are prescribed by the doctor when the body does not produce certain cortisone-like hormones that are necessary to maintain good health. The use of these medicines in Addison's disease treatment owing to their effectiveness will increase its demand in the market which will further be anticipated to drive the growth of the market. The corticosteroids are of two types of Hydrocortisone, and Fludrocortisone. Both are used as a replacement treatment for adrenal glands in case of less production of natural corticosteroids.

Regional Outlook

Geographically, the global Addison's Disease market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, and Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, ASEAN and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). Europe is expected to hold the second-largest position in Addison's disease market. The factors attributed to the growth of this region include rising healthcare expenditure and the presence of key market players. Asia -Pacific is expected to be the fastest-growing region during the forecast period owing to the rising awareness about the disease among the population and increasing R&D activities by major market players for the development and production of new treatments and drugs.

Global Addison's Disease Market Growth, by Region 2021-2027

Global Addison's Disease Market Growth, by Region

North America will dominate Addison's, Disease Market

By region, North America is projected to dominate the global Addison's disease market during the forecast period. The rising prevalence of the disease, high healthcare expenditure and well-developed health infrastructure are the major factors that propel the growth of Addison's disease market in the region. Apart from this, favorable reimbursement policies and growing government initiatives in the healthcare sector is expected to contribute to the growth of the market. The US is the major contributor with more than 90% share in the north American Addison's disease market

Market Players Outlook

The key players in the global Addison's Disease market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include Pfizer Inc, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Novartis AG, Boehringer Ingelheim International GmbH., Tocris Bioscience, among others. To remain competitive in the market and to generate maximum sales revenue, the market players are adopting various strategies such as mergers & acquisitions, R&D, product launches, and geographical expansions so on.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Addison's disease market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Addison's Disease Industry
• Recovery Scenario of Global Addison's Disease Industry
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Geography

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
  • 3.1.1. Overview
  • 3.1.2. Financial Analysis
  • 3.1.3. SWOT Analysis
  • 3.1.4. Recent Developments
• 3.2. Key Strategy Analysis
• 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Addison's Disease Market, By Diagnosis
  • 5.1.1. Laboratory Testing
  • 5.1.2. Imaging Teste
• 5.2. Global Addison's Disease Market, By Treatment
  • 5.2.1. Oral Corticosteroids
  • 5.2.2. Corticosteroids Injections
• 5.3. Global Addison's Disease Market, ByEnd User
  • 5.3.1. Hospitals and Clinics
  • 5.3.2. Diagnostic Laboratories

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Russia
  • 6.2.7. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korean
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World
  • 6.4.1. Latin America
  • 6.4.2. Middle East Africa

7. Company Profiles

• 7.1. Boehringer Ingelheim International GmbH.
• 7.2. Diurnal Group plc
• 7.3. GlaxoSmithKline plc
• 7.4. Laboratory Corporation of America
• 7.5. Lupin Pharmaceuticals, Inc.,
• 7.6. Merck KGaA
• 7.7. Novartis AG
• 7.8. Pfizer Inc.
• 7.9. Tocris Bioscience
• 7.10. Trinity Biotech PLC
• 7.11. ViroPharma